Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (16352)	10/12/2003 11:13:46 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

Robert, original gelonin work failed. It was brought back with new improved twist and then Xoma decided not to bring it clinic as they thought they would. The $10 million was a payment for work in progress. It was not a pure profit penalty. Even so it was and is $10 million, but again it pays Xoma for expenses incurred. I love BPI but does Xoma? You are good at finding continuation of old patents but reluctant to answer why Xoma is not even funding the probes. If Xoma had a real interest where are the clinical trials on fungus? Why does Xoma cite Aiello's work done years ago when he and the Harvard eye clinic appear to have moved on?

To: Robert K. who wrote (16352)	10/12/2003 2:04:12 PM
From: Bluegreen	Respond to of 17367

YEEEEEEHAAAAAAAA!!!!!!!!!!!!!!!!!!! IST IST IST IST.................INVESTIGATOR-SPONSORED TRIAL program!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!>>>>>>>>>>>>>>>>>>>>>>http://www.genentech.com/gene/careers/jobs/detail.jsp?detail=3044396